
Opinion|Videos|June 25, 2024
Adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
Advertisement
Episodes in this series

Now Playing
- While the follow-up data for the
AReSVi-006 trial have not been published, what key results thus far have led to the approval of the adjuvanted vaccine?- Efficacy of preventing RSV-related lower respiratory tract disease
- Adverse effects
- Trial limitations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































